Advanced Non-Small Cell Lung Carcinoma: The Emerging Role of Docetaxel

摘要: The treatment of advanced non-small cell lung carcinoma (NSCLC) has improved greatly over the past decade. With advent new agents, in particular taxanes, gemcitabine, vinorelbine, and topoisomerase I inhibitors, response rates have from 15-20% to 25-35%, with commensurate improvement median one year survival 8-10 months 35-45%, respectively. These improvements proven statistically significant multiple studies [1-4]. Docetaxel, either alone or combination platinols, shown promise; and, some arenas, it become a standard component our therapeutic armamentarium. We will review preclinical data single agent activity docetaxel treatment-naive previously treated NSCLC patients, its cisplatin carboplatin, as well other finally focus on ongoing evaluating role locally disease.